stockrowTakeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
- Revenue
- +1.71%
- EPS
- −4.35%
- Free cash flow
- +54.9%
- Total debt
- −7.28%
Quarter to September 2026, against a year earlier
Follow TAK
Alert me
Takeda Pharmaceutical Co. (TAK) Shares outstanding
Takeda Pharmaceutical Co.'s shares outstanding at the end of fiscal 2026 was $3.2B, unchanged from fiscal 2025. At the end of the quarter to 30 June 2026 it was $3.2B. Over the past ten years it has ranged from $1.6B (fiscal 2017) to $3.2B (fiscal 2025); the current reading is higher than 75% of that period. Takeda Pharmaceutical Co. ranks 2nd of 81 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2026 | $3.2B | (1.89%) |
| FY2025 | $3.2B | 1.58% |
| FY2024 | $3.2B | 0.67% |
| FY2023 | $3.1B | (0.46%) |
| FY2022 | $3.2B | 0.23% |
| FY2021 | $3.1B | 0.47% |
| FY2020 | $3.1B | 61.98% |
| FY2019 | $1.9B | 22.90% |
| FY2018 | $1.6B | 0.10% |
| FY2017 | $1.6B | (0.29%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $3.2B | 0.97% |
| Jun 2025 | $3.1B | (0.27%) |
| Jun 2024 | $3.1B | (0.72%) |
| Mar 2024 | $3.2B | (0.30%) |
| 25 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | $4.6B |
| TAK Takeda Pharmaceutical Co. | $3.2B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $1.2B |
| VTRS Viatris Inc. compare | $1.2B |
| RDY Dr. Reddy's Laboratories Ltd compare | $833.3M |
| ELAN Elanco Animal Health Incorporated compare | $505.9M |
| ZTS Zoetis Inc. compare | $417.7M |
| NBIX Neurocrine Biosciences, Inc. compare | $105.2M |
| UTHR United Therapeutics Corporation compare | $45.3M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on TAK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement